
ANIP
ANI Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $1.94B | Price | $79.48 |
| Volume | 167.58K | Change | -0.65% |
| P/E Ratio | -105.0 | Open | $80.16 |
| Revenue | $614.4M | Prev Close | $80.00 |
| Net Income | $-18.5M | 52W Range | $54.10 - $99.50 |
| Div Yield | N/A | Target | $110.38 |
| Overall | 39 | Value | 55 |
| Quality | 42 | Technical | 20 |
No chart data available
About ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Latest News
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Abeona Therapeutics (ABEO) and Akebia Therapeutics (AKBA)
Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANIP | $79.48 | -0.6% | 167.58K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ANI Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW